{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:07:40Z","timestamp":1767337660875,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T00:00:00Z","timestamp":1534896000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13063-018-2798-x","type":"journal-article","created":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T04:34:49Z","timestamp":1534912489000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-7348","authenticated-orcid":false,"given":"Wieneke M. T.","family":"van den Hombergh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigit E.","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanneke K. A.","family":"Knaapen-Hans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogier M.","family":"Thurlings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"van der Kraan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank H. J.","family":"van den Hoogen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaap","family":"Fransen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madelon C.","family":"Vonk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,22]]},"reference":[{"issue":"5","key":"2798_CR1","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/ard.2008.096677","volume":"68","author":"O Kowal-Bielecka","year":"2009","unstructured":"Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR scleroderma trials and research group (EUSTAR). Ann Rheum Dis. 2009;68(5):620\u20138.","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"2798_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s12016-009-8193-3","volume":"40","author":"M Geyer","year":"2011","unstructured":"Geyer M, Muller-Ladner U. The pathogenesis of systemic sclerosis revisited. Clin Rev Allergy Immunol. 2011;40(2):92\u2013103.","journal-title":"Clin Rev Allergy Immunol."},{"issue":"5","key":"2798_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1056\/NEJMoa1114576","volume":"370","author":"L van Bon","year":"2014","unstructured":"van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med. 2014;370(5):433\u201343.","journal-title":"N Engl J Med."},{"issue":"5","key":"2798_CR4","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/ng.565","volume":"42","author":"TR Radstake","year":"2010","unstructured":"Radstake TR, Gorlova O, Rueda B, Martin JE, Alizadeh BZ, Palomino-Morales R, et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet. 2010;42(5):426\u20139.","journal-title":"Nat Genet."},{"issue":"1","key":"2798_CR5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11926-012-0297-8","volume":"15","author":"MB Greenblatt","year":"2013","unstructured":"Greenblatt MB, Aliprantis AO. The immune pathogenesis of scleroderma: context is everything. Curr Rheumatol Rep. 2013;15(1):297.","journal-title":"Curr Rheumatol Rep."},{"issue":"2","key":"2798_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.patbio.2015.03.003","volume":"63","author":"T Hua-Huy","year":"2015","unstructured":"Hua-Huy T, Dinh-Xuan AT. Cellular and molecular mechanisms in the pathophysiology of systemic sclerosis. Pathol Biol (Paris). 2015;63(2):61\u20138.","journal-title":"Pathol Biol (Paris)"},{"issue":"12","key":"2798_CR7","doi-asserted-by":"publisher","first-page":"e85032","DOI":"10.1371\/journal.pone.0085032","volume":"8","author":"X Xing","year":"2013","unstructured":"Xing X, Yang J, Yang X, Wei Y, Zhu L, Gao D, et al. IL-17A induces endothelial inflammation in systemic sclerosis via the ERK signaling pathway. PLoS One. 2013;8(12):e85032.","journal-title":"PLoS One"},{"issue":"6","key":"2798_CR8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/BOR.0b013e32832fd69e","volume":"21","author":"R Lafyatis","year":"2009","unstructured":"Lafyatis R, York M. Innate immunity and inflammation in systemic sclerosis. Curr Opin Rheumatol. 2009;21(6):617\u201322.","journal-title":"Curr Opin Rheumatol."},{"issue":"1","key":"2798_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.autrev.2011.06.007","volume":"11","author":"I Marie","year":"2011","unstructured":"Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev. 2011;11(1):6\u201313.","journal-title":"Autoimmun Rev."},{"issue":"5","key":"2798_CR10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.7326\/0003-4819-83-5-597","volume":"83","author":"BH Hahn","year":"1975","unstructured":"Hahn BH, Kantor OS, Osterland CK. Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients. Ann Intern Med. 1975;83(5):597\u2013605.","journal-title":"Ann Intern Med."},{"issue":"16","key":"2798_CR11","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMra050541","volume":"353","author":"T Rhen","year":"2005","unstructured":"Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711\u201323.","journal-title":"N Engl J Med."},{"issue":"2 Suppl 76","key":"2798_CR12","first-page":"157","volume":"31","author":"M Iudici","year":"2013","unstructured":"Iudici M, van der Goes MC, Valentini G, Bijlsma JW. Glucocorticoids in systemic sclerosis: weighing the benefits and risks - a systematic review. Clin Exp Rheumatol. 2013;31(2 Suppl 76):157\u201365.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"2798_CR13","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/rheumatology\/keq374","volume":"50","author":"L Czirjak","year":"2011","unstructured":"Czirjak L, Matucci-Cerinic M. Beyond Raynaud's phenomenon hides very early systemic sclerosis: the assessment of organ involvement is always mandatory. Rheumatology (Oxford). 2011;50(2):250\u20131.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"2798_CR14","first-page":"2371","volume":"29","author":"B Griffiths","year":"2002","unstructured":"Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol. 2002;29(11):2371\u20138.","journal-title":"J Rheumatol."},{"issue":"2","key":"2798_CR15","first-page":"287","volume":"25","author":"M Vanthuyne","year":"2007","unstructured":"Vanthuyne M, Blockmans D, Westhovens R, Roufosse F, Cogan E, Coche E, et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol. 2007;25(2):287\u201392.","journal-title":"Clin Exp Rheumatol."},{"issue":"12","key":"2798_CR16","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1136\/annrheumdis-2013-203716","volume":"73","author":"T Minier","year":"2014","unstructured":"Minier T, Guiducci S, Bellando-Randone S, Bruni C, Lepri G, Czirjak L, et al. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis. 2014;73(12):2087\u201393.","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"2798_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1136\/annrheumdis-2012-202295","volume":"72","author":"M Matucci-Cerinic","year":"2013","unstructured":"Matucci-Cerinic M, Bellando-Randone S, Lepri G, Bruni C, Guiducci S. Very early versus early disease: the evolving definition of the 'many faces' of systemic sclerosis. Ann Rheum Dis. 2013;72(3):319\u201321.","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"2798_CR18","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/annrheumdis-2011-200780","volume":"71","author":"V Smith","year":"2012","unstructured":"Smith V, Decuman S, Sulli A, Bonroy C, Piettte Y, Deschepper E, et al. Do worsening scleroderma capillaroscopic patterns predict future severe organ involvement?a pilot study. Ann Rheum Dis. 2012;71(10):1636\u20139.","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"2798_CR19","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/ard.2005.043240","volume":"64","author":"JM van Laar","year":"2005","unstructured":"van Laar JM, Farge D, Tyndall A. Autologous stem cell transplantation international scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis. Ann Rheum Dis. 2005;64(10):1515.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"2798_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/ard.2007.082495","volume":"68","author":"I Miniati","year":"2009","unstructured":"Miniati I, Guiducci S, Conforti ML, Rogai V, Fiori G, Cinelli M, et al. Autologous stem cell transplantation improves microcirculation in systemic sclerosis. Ann Rheum Dis. 2009;68(1):94\u20138.","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"2798_CR21","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/acr.22304","volume":"66","author":"G Valentini","year":"2014","unstructured":"Valentini G, Marcoccia A, Cuomo G, Vettori S, Iudici M, Bondanini F, et al. Early systemic sclerosis: analysis of the disease course in patients with marker autoantibody and\/or capillaroscopic positivity. Arthritis Care Res (Hoboken). 2014;66(10):1520\u20137.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"8","key":"2798_CR22","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327\u201339.","journal-title":"Ann Rheum Dis."},{"issue":"5234","key":"2798_CR23","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1126\/science.270.5234.286","volume":"270","author":"N Auphan","year":"1995","unstructured":"Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270(5234):286\u201390.","journal-title":"Science"},{"issue":"2","key":"2798_CR24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.humpath.2005.10.007","volume":"37","author":"CA Davies","year":"2006","unstructured":"Davies CA, Jeziorska M, Freemont AJ, Herrick AL. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol. 2006;37(2):190\u20137.","journal-title":"Hum Pathol."},{"issue":"8","key":"2798_CR25","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/qjmed\/91.8.561","volume":"91","author":"RJ Stratton","year":"1998","unstructured":"Stratton RJ, Coghlan JG, Pearson JD, Burns A, Sweny P, Abraham DJ, et al. Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. QJM. 1998;91(8):561\u20136.","journal-title":"QJM"},{"issue":"3","key":"2798_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/gene.2011.61","volume":"13","author":"SA Greenberg","year":"2012","unstructured":"Greenberg SA, Higgs BW, Morehouse C, Walsh RJ, Kong SW, Brohawn P, et al. Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun. 2012;13(3):207\u201313.","journal-title":"Genes Immun."},{"issue":"11","key":"2798_CR27","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1136\/ard.2011.150326","volume":"70","author":"BW Higgs","year":"2011","unstructured":"Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis. 2011;70(11):2029\u201336.","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"2798_CR28","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747\u201355.","journal-title":"Ann Rheum Dis"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2798-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-2798-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-2798-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T19:15:46Z","timestamp":1566414946000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-2798-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,22]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2798"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-2798-x","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2018,8,22]]},"assertion":[{"value":"11 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study received ethical review board approval: CMO Regio Arnhem-Nijmegen (2015\u2013004613-24).Informed consent from all participants in the study is obtained by one of the study doctors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"449"}}